80 related articles for article (PubMed ID: 9526174)
1. Potential interest of anti-ischemic agents for limiting cyclosporin A nephrotoxicity.
Simon N; Tillement JP; Albengres E; Jaber K; Hestin D; Roux F; Olivier P; d'Athis P; Kessler M; Berland Y; Crevat A
Int J Clin Pharmacol Res; 1997; 17(4):133-42. PubMed ID: 9526174
[TBL] [Abstract][Full Text] [Related]
2. [Value of protecting mitochondrial functions during treatment with cyclosporin A].
Simon N; Albengres E; Barré J; Jolliet P; Urien S; Settaf A; Tillement JP
Therapie; 1997; 52(2):151-4. PubMed ID: 9231511
[TBL] [Abstract][Full Text] [Related]
3. Trimetazidine reverses calcium accumulation and impairment of phosphorylation induced by cyclosporine A in isolated rat liver mitochondria.
Salducci MD; Chauvet-Monges AM; Tillement JP; Albengres E; Testa B; Carrupt P; Crevat A
J Pharmacol Exp Ther; 1996 Apr; 277(1):417-22. PubMed ID: 8613950
[TBL] [Abstract][Full Text] [Related]
4. [Effects of trimetazidine on altered functions of rat kidney induced by cyclosporine].
Simon N; Morin C; Bruguerolle B; Tillement JP
Therapie; 2001; 56(5):583-7. PubMed ID: 11806297
[TBL] [Abstract][Full Text] [Related]
5. Trimetazidine counteracts the hepatic injury associated with ischemia-reperfusion by preserving mitochondrial function.
Elimadi A; Settaf A; Morin D; Sapena R; Lamchouri F; Cherrah Y; Tillement JP
J Pharmacol Exp Ther; 1998 Jul; 286(1):23-8. PubMed ID: 9655837
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological modulation of mitochondrial oxidative phosphorylation: inhibition by cyclosporine A, restoration by trimetazidine].
Tillement JP; Crevat A; Testa B; Le Ridant A
Ann Pharm Fr; 1996; 54(6):268-71. PubMed ID: 9008901
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of rat cerebral mitochondrial respiration by cyclosporins A, D, and G and restoration with trimetazidine.
Zini R; Simon N; Morin C; d'Athis P; Tillement JP
C R Acad Sci III; 1996 Dec; 319(12):1087-92. PubMed ID: 9091178
[TBL] [Abstract][Full Text] [Related]
8. Evidence for the existence of [3H]-trimetazidine binding sites involved in the regulation of the mitochondrial permeability transition pore.
Morin D; Elimadi A; Sapena R; Crevat A; Carrupt PA; Testa B; Tillement JP
Br J Pharmacol; 1998 Apr; 123(7):1385-94. PubMed ID: 9579734
[TBL] [Abstract][Full Text] [Related]
9. Trimetazidine in the myocardial cell mechanisms of cytoprotection.
Labrid C
Rom J Intern Med; 1998; 36(3-4):137-44. PubMed ID: 10822510
[TBL] [Abstract][Full Text] [Related]
10. Lipophilic dihydropyridines provide renal protection from cyclosporin toxicity.
Rodicio JL; Morales JM; Ruilope LM
J Hypertens Suppl; 1993 Dec; 11(6):S21-5. PubMed ID: 8169378
[TBL] [Abstract][Full Text] [Related]
11. [Enhancement of antioxidant status of the elderly patients with ischemic heart disease in response to amino acid composition of MP-33 in combined therapy with trimetazidine].
Kalinina EB; Komissarova IA; Zaslavskaia RM; Zhdanov IuA
Klin Med (Mosk); 2002; 80(5):50-3. PubMed ID: 12087889
[TBL] [Abstract][Full Text] [Related]
12. [Trimetazidine (Preductal). A new approach in controlling myocardial ischemia].
Eliseev OM
Ter Arkh; 1996; 68(8):57-63. PubMed ID: 9019836
[No Abstract] [Full Text] [Related]
13. Protective effect of trimetazidine on myocardial mitochondrial function in an ex-vivo model of global myocardial ischemia.
Monteiro P; Duarte AI; Gonçalves LM; Moreno A; Providência LA
Eur J Pharmacol; 2004 Oct; 503(1-3):123-8. PubMed ID: 15496306
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological manipulation of acute cyclosporin ischemic renal injury with trimetazidine.
Creagh T; Lanigan D; Dolan J; Tormey W; Walshe JJ; Bouchier-Hayes D
J Urol; 1993 Apr; 149(4):915-7. PubMed ID: 8455274
[TBL] [Abstract][Full Text] [Related]
15. Trimetazidine protects the energy status after ischemia and reduces reperfusion injury in a rat single lung transplant model.
Inci I; Dutly A; Rousson V; Boehler A; Weder W
J Thorac Cardiovasc Surg; 2001 Dec; 122(6):1155-61. PubMed ID: 11726890
[TBL] [Abstract][Full Text] [Related]
16. [Efficiency of trimetazidine treatment of experimental ischemic heart disease in age aspect].
Kukes VG; Zhernakova NI; Gorbach TV; Romashchenko OV; Rumbesht VV
Eksp Klin Farmakol; 2013; 76(2):9-12. PubMed ID: 23631276
[TBL] [Abstract][Full Text] [Related]
17. [Mediators involved in the nephrotoxicity of cyclosporin A].
Simon N; Barré J; Jolliet P; Urien S; Tillement JP
Therapie; 1997; 52(4):329-33. PubMed ID: 9437887
[TBL] [Abstract][Full Text] [Related]
18. Role of trimetazidine in management of ischemic cardiomyopathy.
Bertomeu-Gonzalez V; Bouzas-Mosquera A; Kaski JC
Am J Cardiol; 2006 Sep; 98(5A):19J-24J. PubMed ID: 16931202
[TBL] [Abstract][Full Text] [Related]
19. Increase of adenosine plasma levels after oral trimetazidine: a pharmacological preconditioning?
Blardi P; de Lalla A; Volpi L; Auteri A; Di Perri T
Pharmacol Res; 2002 Jan; 45(1):69-72. PubMed ID: 11820865
[TBL] [Abstract][Full Text] [Related]
20. [Trimetazidine and cardioprotection during ischemia-reperfusion].
Barsotti A; Di Napoli P
Ital Heart J; 2004 Mar; 5 Suppl 2():29S-36S. PubMed ID: 15074775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
